Pretreatment of BC cells with 0.25 mM (Fig. 5B) and 0.50 mM (data not shown) of the specific tyrosine-phosphatase inhibitor, orthovanadate for 30 min prior to treatment with sorafenib (20 μM) strongly reduced at 12 h after treatment, the percentage of sorafenib-induced Ann V apoptotic cells, as evaluated by FACS analysis (Fig. 5B).
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}